Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

Annals of Hematology

Volumn 91, Issue 8, 2012, Pages 1289-1297

  Michallet, Mauricette ^a,g   Sobh, Mohamad ^a   Milpied, Noel ^b   Bay, Jacques Olivier ^c   Fürst, Sabine ^d   Harousseau, Jean Luc ^e   Mohty, Mohamad ^e   Nicolini, Franck E ^a   Labussière, Hélène ^a   Tedone, Nathalie ^a   Morisset, Stéphane ^a   Vigouroux, Stéphane ^b   Baumgart, Joachim ^f   Tabrizi, Reza ^b   Blaise, Didier ^d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f MEDAC GMBH   (Germany)

^g CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Allo HSCT; ATG; Fludarabine; Treosulfan

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; RITUXIMAB; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; BONE PAIN; CANCER RELAPSE; CARDIOVASCULAR SYMPTOM; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TOLERABILITY; EPSTEIN BARR VIRUS INDUCED LYMPHOMA; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HEMATOLOGICAL PARAMETERS; HLA MATCHING; HUMAN; INCIDENCE; INFECTION; KIDNEY DISEASE; LUNG DISEASE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; MULTICENTER STUDY; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NEUTROPHIL RECOVERY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PLATELET RECOVERY; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SEPTICEMIA; SKIN MANIFESTATION; TRANSPLANT RELATED MORTALITY; UNRELATED DONORS; UROGENITAL TRACT DISEASE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84864972302     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1429-y     Document Type: Article

References (40)

1. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant JP, Michallet M, Buzyn A, Gratecos N, Cahn JY, Bourhis JH, Chir Z, Raffoux C, Socie G, Golmard JL, Jouet JP (2006) Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 24(36):5695-5702 (Pubitemid 46631311)
2. Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, Petersdorf E, Nelson G, McGlave P (2002) Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99(6):1971-1977 (Pubitemid 34525477)
3. Michallet M, Sobh M, Milligan D, Morisset S, Niederwieser D, Koza V, Ruutu T, Russell NH, Verdonck L, Dhedin N, Vitek A, Boogaerts M, Vindelov L, Finke J, Dubois V, van Biezen A, Brand R, de Witte T, Dreger P (2010) The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia 24(10):1725-1731
4. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, Horowitz M, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D (2004) Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLAC mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104(7):1923-1930 (Pubitemid 39297840)
5. Dini G, Cancedda R, Locatelli F, Bosi A, Bandini G, Alessandrino EP, Porta F, Uderzo C, Messina C, Fagioli F, ArceseW, Marenco P, Fanin R, Falda M, Soligo D, La Nasa G, Giardini C, Pession A, Scime R, Di Bartolomeo P, Bruno B, Garbarino L, Lamparelli T, Giorgiani G, Lanino E, Manzitti C, Bacigalupo A (2001) Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO). Haematologica 86(5):451-456 (Pubitemid 33638971)
6. Bierman PJ, Sweetenham JW, Loberiza FR Jr, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A (2003) Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 21(20):3744-3753 (Pubitemid 46606228)
7. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE et al (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 11(12):2342-2350 (Pubitemid 23353963)
8. Khouri IF, Keating MJ, Saliba RM, Champlin RE (2002) Longterm follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 4(3):217-221
9. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6 (10):1562-1568 (Pubitemid 19092391)
10. Balduzzi A, Valsecchi MG, Silvestri D, Locatelli F, Manfredini L, Busca A, Iori AP, Messina C, Prete A, Andolina M, Porta F, Favre C, Ceppi S, Giorgiani G, Lanino E, Rovelli A, Fagioli F, De Fusco C, Rondelli R, Uderzo C (2002) Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant 29 (2):93-100 (Pubitemid 34144839)
11. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3):756-763 (Pubitemid 28078275)
12. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin R (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97(3):631-637 (Pubitemid 32113394)
13. Gropp M, Meier W, Hepp H (1998) Treosulfan as an effective second-line therapy in ovarian cancer. Gynecol Oncol 71(1):94-98 (Pubitemid 28492400)
14. Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schafer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kroger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M (2010) Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 28(20):3344-3351
15. Markiewicz M, Wojciechowska M, Wylezol I, Giebel S, Wozniczka K, Wojnar J, Mendek-Czajkowska E, Holowiecki J (2005) First two successful unrelated donor bone marrow transplantations for paroxysmal nocturnal hemoglobinuria in Poland. Ann Transplant 10 (3):26-30
16. Kroger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A (2006) Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant 37(4):339-344 (Pubitemid 43250466)
17. Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A (2007) Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 48 (12):2352-2359 (Pubitemid 350258301)
18. Casper J, Knauf W, Kiefer T, Wolff D, Steiner B, Hammer U, Wegener R, Kleine HD, Wilhelm S, Knopp A, Hartung G, Dolken G, Freund M (2004) Treosulfan and fludarabine: a new toxicityreduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103(2):725-731 (Pubitemid 38140111)
19. Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H, Kanz L, Keilholz U, Marinets O, Beelen DW, Fauser AA, Volin L, Ruutu T, Uharek L, Fietz T, Knauf W, Hopfenmuller W, Thiel E, Freund M, Casper J (2007) Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 39(7):389-396 (Pubitemid 46487303)
20. Blau IW, Schmidt-Hieber M, Leschinger N, Goldner H, Knauf W, Hopfenmuller W, Thiel E, Blau O (2007) Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stemcell transplantation. Ann Hematol 86(8):583-589 (Pubitemid 47022827)
21. Baronciani D, Rambaldi A, Iori AP, Di Bartolomeo P, Pilo F, Pettinau M, Depau C, Mico C, Santarone S, Angelucci E (2008) Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol 83(9):717-720
22. Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, Caocci G, Comoli P, Mastronuzzi A, Merli P, La Nasa G, Locatelli F (2008) Treosulfan-based conditioning regimen for allogeneic haematopoietic stemcell transplantation in patients with thalassaemia major. Br J Haematol 143(4):548-551
23. Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J (2011) Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. Haematologica 96(9):1344-1350
24. Lapierre V, Oubouzar N, Auperin A, Tramalloni D, Tayebi H, Robinet E, Kuentz M, Blaise D, Hartmann O, Herve P, Tiberghien P (2001) Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood 97(9):2580-2586
25. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18(4):295-304
26. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM (1988) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72(2):520-529
27. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457
28. Cox DR (1972) Regression models and life tables. J Royal Stat Soc B 34:187-220
29. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S (2004) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104(3):865-872 (Pubitemid 38970586)
30. Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, Nagler A (2007) Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapsemortality and lower incidence of relapse than fludarabine/busulfan. Leukemia 21(10):2109-2116 (Pubitemid 47423801)
31. Dasgupta RK, Rule S, Johnson P, Davies J, Burnett A, Poynton C, Wilson K, Smith GM, Jackson G, Richardson C,Wareham E, Stars AC, Tollerfield SM, Morgan GJ (2006) Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplant 37(5):455-461
32. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R (1996) Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17(2):225-230 (Pubitemid 26057312)
33. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: a multiinstitutional study. Blood 94(7):2208-2216 (Pubitemid 29467666)
34. Mohty M, Labopin M, Balere ML, Socie G, Milpied N, Tabrizi R, Ifrah N, Hicheri Y, Dhedin N, Michallet M, Buzyn A, Cahn JY, Bourhis JH, Blaise D, Raffoux C, Esperou H, Yakoub-Agha I (2010) Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLAmatched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 24(11):1867-1874
35. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers ME, Mielcarek M, Maloney DG, Storb R (2005) Graft-versustumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23(9):1993-2003 (Pubitemid 46211379)
36. Klumpp TR, Herman JH, Ulicny J, Emmons RV, Martin ME, Mangan KF (2006) Lack of effect of donor-recipient ABO mismatching on outcome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 38(9):615-620 (Pubitemid 44596853)
37. Kanda J, Ichinohe T, Matsuo K, Benjamin RJ, Klumpp TR, Rozman P, Blumberg N, Mehta J, Sohn SK, Uchiyama T (2009) Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. Transfusion 49(4):624-635
38. Nemecek ER, Guthrie KA, Sorror ML, Wood BL, Doney KC, Hilger RA, Scott BL, Kovacsovics TJ, Maziarz RT, Woolfrey AE, Bedalov A, Sanders JE, Pagel JM, Sickle EJ, Witherspoon R, Flowers ME, Appelbaum FR, Deeg HJ (2011) Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 17(3):341-350
39. Blaise D, Farnault L, Faucher C, Marchetti N, Furst S, El Cheikh J, Ladaique P, Vey N, Bouabdallah R, Stoppa AM, Lemarie C, Calmels B, Prebet T, Castagna L, Chabannon C, Mohty M, Esterni B (2010) Reduced-intensity conditioning with fludarabin, oral busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Exp Hematol 38(12):1241-1250
40. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schafer-Eckardt K, Beyer J, Kiehl M, Zander AR (2003) Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82(6):336-342 (Pubitemid 36806015)